US HB1046 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Democrat 128-0)
Status: Introduced on February 7 2019 - 25% progression, died in chamber
Action: 2019-09-25 - Subcommittee Hearings Held.
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 7 2019 - 25% progression, died in chamber
Action: 2019-09-25 - Subcommittee Hearings Held.
Text: Latest bill text (Introduced) [PDF]
Summary
Requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.) The CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities. Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).
Title
Medicare Negotiation and Competitive Licensing Act of 2019
Sponsors
History
Date | Chamber | Action |
---|---|---|
2019-09-25 | House | Subcommittee Hearings Held. |
2019-02-08 | House | Referred to the Subcommittee on Health. |
2019-02-07 | House | Referred to the Subcommittee on Health. |
2019-02-07 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2019-02-07 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
2019-02-07 | House | Introduced in House |
Same As/Similar To
SB377 (Related) 2019-02-07 - Read twice and referred to the Committee on Finance.
Subjects
Competition and antitrust
Drug safety, medical device, and laboratory regulation
Health
Health care costs and insurance
Inflation and prices
Licensing and registrations
Manufacturing
Medicare
Prescription drugs
Product safety and quality
Public contracts and procurement
Drug safety, medical device, and laboratory regulation
Health
Health care costs and insurance
Inflation and prices
Licensing and registrations
Manufacturing
Medicare
Prescription drugs
Product safety and quality
Public contracts and procurement
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/1046/all-info |
Text | https://www.congress.gov/116/bills/hr1046/BILLS-116hr1046ih.pdf |